Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis

Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis

(2013) Lesley J. Scott   CNS DRUGS

Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice

(2013) Mark S. Freedman et al.   Multiple Sclerosis and Related Disorders

Teriflunomide added to interferon-  in relapsing multiple sclerosis: A randomized phase II trial

(2012) M. S. Freedman et al.   NEUROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

(2011) Bernd C. Kieseier   CNS DRUGS

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

(2009) M. Trojano et al.   ANNALS OF NEUROLOGY

Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis

(2009) Massimiliano Calabrese et al.   ARCHIVES OF NEUROLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY